ES2164465T3 - Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. - Google Patents
Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.Info
- Publication number
- ES2164465T3 ES2164465T3 ES98961174T ES98961174T ES2164465T3 ES 2164465 T3 ES2164465 T3 ES 2164465T3 ES 98961174 T ES98961174 T ES 98961174T ES 98961174 T ES98961174 T ES 98961174T ES 2164465 T3 ES2164465 T3 ES 2164465T3
- Authority
- ES
- Spain
- Prior art keywords
- neuronal
- aminometil
- chromans
- replaced
- avoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000004770 neurodegeneration Effects 0.000 title 1
- 230000009689 neuronal regeneration Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- BSRHATGBRQMDRF-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ylmethanamine Chemical group C1=CC=C2OC(CN)CCC2=C1 BSRHATGBRQMDRF-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19751949A DE19751949A1 (de) | 1997-11-24 | 1997-11-24 | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2164465T3 true ES2164465T3 (es) | 2002-02-16 |
Family
ID=7849618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98961174T Expired - Lifetime ES2164465T3 (es) | 1997-11-24 | 1998-11-11 | Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6235774B1 (https=) |
| EP (1) | EP1051170B1 (https=) |
| JP (1) | JP2001523716A (https=) |
| KR (1) | KR20010032357A (https=) |
| CN (1) | CN1134256C (https=) |
| AR (1) | AR016973A1 (https=) |
| AT (1) | ATE206615T1 (https=) |
| AU (1) | AU745759B2 (https=) |
| BG (1) | BG64167B1 (https=) |
| CA (1) | CA2311126A1 (https=) |
| DE (2) | DE19751949A1 (https=) |
| DK (1) | DK1051170T3 (https=) |
| ES (1) | ES2164465T3 (https=) |
| HN (1) | HN1998000169A (https=) |
| HU (1) | HUP0004369A3 (https=) |
| IL (1) | IL135904A (https=) |
| IS (1) | IS5496A (https=) |
| MY (1) | MY118414A (https=) |
| NO (1) | NO20002638D0 (https=) |
| NZ (1) | NZ504656A (https=) |
| PE (1) | PE134999A1 (https=) |
| PL (1) | PL340674A1 (https=) |
| PT (1) | PT1051170E (https=) |
| RU (1) | RU2217140C2 (https=) |
| SI (1) | SI1051170T1 (https=) |
| SV (1) | SV1998000138A (https=) |
| TR (1) | TR200001471T2 (https=) |
| TW (1) | TW524690B (https=) |
| WO (1) | WO1999026621A1 (https=) |
| ZA (1) | ZA9810668B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| MXPA02009071A (es) * | 2000-03-17 | 2003-05-23 | Alcon Inc | Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma.. |
| US20030207890A1 (en) | 2001-02-23 | 2003-11-06 | Collier Robert J | Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| DE10058119A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Pepinotan-Kit |
| SE0004455D0 (sv) * | 2000-12-01 | 2000-12-01 | Milos Pekny | Method for neuron regeneration in the central nervous system |
| DE10101917A1 (de) * | 2001-01-16 | 2002-07-18 | Bayer Ag | Verwendung von Chromanen |
| PT1408964E (pt) * | 2001-07-26 | 2007-05-31 | Merck Patent Gmbh | Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis. |
| ATE341322T1 (de) * | 2001-09-12 | 2006-10-15 | Merck Patent Gmbh | Verwendung von aminomethyl chromanen zur behandlung der nebenwirkungen von neuroleptika |
| DE10155075A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Cyclische Sulfonamide |
| ITTO20030140U1 (it) * | 2003-09-16 | 2005-03-17 | Interfila Srl | Matita cosmetica |
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| DE102004017627A1 (de) * | 2004-04-10 | 2005-10-27 | Bayer Healthcare Ag | Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression |
| PT3494119T (pt) | 2016-07-29 | 2024-12-10 | Pgi Drug Discovery Llc | Compostos e composições e seus usos |
| MA45795A (fr) | 2016-07-29 | 2019-06-05 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
| RU2651756C1 (ru) * | 2017-05-10 | 2018-04-23 | Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ | Препарат для предотвращения образования глиальных рубцов |
| CA3070993C (en) * | 2017-08-02 | 2025-05-20 | Sunovion Pharmaceuticals Inc. | ISOCHROMANE COMPOUNDS AND THEIR USES |
| EP3938045A1 (en) | 2019-03-14 | 2022-01-19 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5300523A (en) | 1988-07-28 | 1994-04-05 | Bayer Aktiengesellschaft | Substituted aminomethyltetralins and their heterocyclic analogues |
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| FR2662355B1 (fr) * | 1990-05-22 | 1994-11-10 | Sanofi Sa | Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux. |
| GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| DE4135474A1 (de) | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| DE19522088A1 (de) | 1995-06-19 | 1997-01-02 | Bayer Ag | Benzisothiazolyl-substituierte Aminomethylchromane |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
-
1997
- 1997-11-24 DE DE19751949A patent/DE19751949A1/de not_active Withdrawn
-
1998
- 1998-10-26 HN HN1998000169A patent/HN1998000169A/es unknown
- 1998-11-11 DK DK98961174T patent/DK1051170T3/da active
- 1998-11-11 PT PT81108222T patent/PT1051170E/pt unknown
- 1998-11-11 TW TW087118723A patent/TW524690B/zh not_active IP Right Cessation
- 1998-11-11 CN CNB988114453A patent/CN1134256C/zh not_active Expired - Fee Related
- 1998-11-11 CA CA002311126A patent/CA2311126A1/en not_active Abandoned
- 1998-11-11 ES ES98961174T patent/ES2164465T3/es not_active Expired - Lifetime
- 1998-11-11 TR TR2000/01471T patent/TR200001471T2/xx unknown
- 1998-11-11 US US09/554,971 patent/US6235774B1/en not_active Expired - Fee Related
- 1998-11-11 AT AT98961174T patent/ATE206615T1/de not_active IP Right Cessation
- 1998-11-11 AU AU16685/99A patent/AU745759B2/en not_active Ceased
- 1998-11-11 WO PCT/EP1998/007197 patent/WO1999026621A1/de not_active Ceased
- 1998-11-11 PL PL98340674A patent/PL340674A1/xx unknown
- 1998-11-11 RU RU2000116547/14A patent/RU2217140C2/ru not_active IP Right Cessation
- 1998-11-11 HU HU0004369A patent/HUP0004369A3/hu unknown
- 1998-11-11 NZ NZ504656A patent/NZ504656A/en unknown
- 1998-11-11 DE DE59801724T patent/DE59801724D1/de not_active Expired - Fee Related
- 1998-11-11 KR KR1020007005593A patent/KR20010032357A/ko not_active Ceased
- 1998-11-11 JP JP2000521823A patent/JP2001523716A/ja not_active Withdrawn
- 1998-11-11 EP EP98961174A patent/EP1051170B1/de not_active Expired - Lifetime
- 1998-11-11 SI SI9830038T patent/SI1051170T1/xx unknown
- 1998-11-11 IL IL13590498A patent/IL135904A/xx active IP Right Grant
- 1998-11-19 AR ARP980105881A patent/AR016973A1/es not_active Application Discontinuation
- 1998-11-20 MY MYPI98005285A patent/MY118414A/en unknown
- 1998-11-23 ZA ZA9810668A patent/ZA9810668B/xx unknown
- 1998-11-23 PE PE1998001138A patent/PE134999A1/es not_active Application Discontinuation
- 1998-11-24 SV SV1998000138A patent/SV1998000138A/es unknown
-
2000
- 2000-05-15 IS IS5496A patent/IS5496A/is unknown
- 2000-05-22 BG BG104466A patent/BG64167B1/bg unknown
- 2000-05-23 NO NO20002638A patent/NO20002638D0/no unknown
-
2001
- 2001-03-09 US US09/803,621 patent/US6331561B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2164465T3 (es) | Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. | |
| ES2175161T3 (es) | Derivados de piperazina como antagonistas de taquiquinina. | |
| ES2052717T3 (es) | Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. | |
| ES2139132T3 (es) | Composiciones farmaceuticas activas en la terapia de desordenes del sueño. | |
| ES2161290T3 (es) | Derivados de quinazolina. | |
| ES2182161T3 (es) | Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer. | |
| UY26782A1 (es) | Derivados del benzotiazol | |
| CO4770978A1 (es) | Empleo de epinastina para el tratamiento de dolores | |
| UY25242A1 (es) | Inhibidores de benzotiazol de la proteína tirosina cinasa | |
| ES2166379T3 (es) | 2-aminotetralinas sustituidas. | |
| ES2054860T5 (es) | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. | |
| BR0315296A (pt) | Derivados do ciclohexanol espirocìclicos | |
| PA8550101A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización | |
| UY27092A1 (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| MX9503529A (es) | Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen. | |
| ES2179945T3 (es) | Compuestos de tetralina con actividad de resistencia a multiples farmacos. | |
| AR012504A1 (es) | Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion. | |
| ES2177849T3 (es) | Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer. | |
| AR018505A1 (es) | COMPOSICIoN FARMACÉUTICA ANTIHISTAMíNICA CON UN INHIBIDOR DE LA P-GLICOPROTEíNA Y EL USO DE DICHA COMPOSICIoN PARA LA FABRICACIoN DE MEDICAMENTOS PARA AUMENTAR LA BIODISPONIBILIDAD DE DICHO ANTIHISTAMíNICO. | |
| ES2105285T3 (es) | Nuevos derivados de la adenosina, sus procedimientos de preparacion, composiciones farmaceuticas que los contienen. | |
| ES2066914T3 (es) | Factores a1, a2, a3 y h del antibiotico ge 2270. | |
| ES2161953T3 (es) | Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson. | |
| PE20011260A1 (es) | Derivados de sulfonamida | |
| AR012602A1 (es) | Derivados de amidina, formulacion farmaceutica, uso de dichos derivados para la fabricacion de medicamentos y proceso para la preparacion de dichosderivados | |
| AR012601A1 (es) | Derivados de amidina, formulaciones farmaceuticas que los contiene, uso de dichos derivados en la preparacion de medicamentos y proceso para lapreparacion de dichos derivados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 1051170 Country of ref document: ES |